Please login to the form below

Not currently logged in
Email:
Password:

MEDI1814

This page shows the latest MEDI1814 news and features for those working in and with pharma, biotech and healthcare.

Biogen rises on more positive data for Alzheimer's candidate

Biogen rises on more positive data for Alzheimer's candidate

compounds. . Last week, it partnered with AstraZeneca (AZ) on MEDI1814, an antibody against amyloid-beta 42 (Aβ42) in phase I trials, and is also working with AZ on BACE inhibitor AZD3293,

Latest news

  • Lilly taps AstraZeneca for another anti-amyloid drug Lilly taps AstraZeneca for another anti-amyloid drug

    Lilly and AZ will collaborate on the development of MEDI1814, an antibody against amyloid-beta 42 (Aβ42), which is currently in phase I trials. ... MEDI1814 dose-dependently reduces levels of the Aβ42 peptide - which is thought to be particularly

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics